Welcome to the EPA 2022 Interactive Programme 

Session Description:

Chronic insomnia disorder is the most common sleep–wake disorder worldwide. It is a 24-hour condition with symptoms that affect patients’ nighttime and daytime functioning, presenting a significant burden for patients and healthcare systems. It has a negative effect on many aspects of daily living, such as reducing workplace productivity, and increasing risk of injuries and motor vehicle accidents. Insomnia is also associated with serious long-term health conditions, including psychiatric disorders, cardiovascular diseases and type 2 diabetes. Current treatment approaches for chronic insomnia disorder may not adequately address the needs of all aspects of the condition. This industry-sponsored symposium will examine the impact of chronic insomnia disorder with a focus on daytime functioning. Furthermore, this expert faculty will explore the mechanism of the disease as a causal target for the treatment of this condition and review the data from pivotal clinical trials of daridorexant - a next-generation dual orexin receptor antagonist for the treatment of chronic insomnia disorder. .